DBV Technologies

DBV Technologies SA is a global clinical-stage biopharmaceutical company providing treatments for patients with food and pediatric allergies. The company focuses on discovering, developing, manufacturing, and commercializing treatments for severe allergies in the United States and other global markets. DBV's approach to delivering bioactive compounds to the immune system involves self-administered and non-invasive products for treatment. The company is also exploring potential applications of its platform in vaccines and other immune-related diseases. Our mission is to leverage our innovative technology platform Viaskin™ to advance epicutaneous immunotherapy and develop treatments for immune diseases with significant unmet medical needs.